Genome‐wide methylation and QMSP have shown that CCND2 promoter hypermethylation was detected in 40.9% of breast tumors and 44.4% of plasma circulating cfDNA of patients, and could serve as a potential diagnostic and prognostic marker in breast cancer [36]. Here, CCND2 is linked to breast carcinoma.